Role of the microenvironment in hepatocellular carcinoma development and progression

Wu, Shengdi; Ma, Yu‐Shui; Fāng, Yīng; Liu, Li‐Li; Fu, Da; Shen, Xizhong

doi:10.1016/j.ctrv.2011.06.010

Cited by 112 publications

(88 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has long been accepted that growing HCC tumor masses can destroy or replay liver parenchyma and thus enhance liver damage. There is now evidence that the converse is also likely true and that liver micro environmental factors may influence HCC growth and invasion [12][13][14][15][16][17][18][19]. Molecular signatures of the underlying liver in HCC patients provide support for this idea [25][26][27], as well as recently reported clinical associations of changes in liver function with HCC biology [3].…”

Section: Discussionmentioning

confidence: 89%

“…As a result, elements of both sets of factors are included in most HCC classification and prognostication systems [10] with increasing refinements [11]. The underlying liver has been increasingly understood as a complex dynamic of cells, tissues, inflammatory cytokines and growth factors [12][13][14][15][16][17][18]. This has been most extensively studied with respect to the neo vascular endothelial cells that form the blood vessels that are needed to support the growing tumor mass, and are an important target for various multikinase inhibitors, which are used in cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels

Carr¹,

Guerra²

2016

J Integr Oncol

View full text Add to dashboard Cite

Four HCC characteristics typically inform tumor behavior: maximum tumor size, number of nodules, portal vein thrombosis and serum AFP level. The sum of these parameters was recently published as an HCC Aggressiveness Index. We aimed to validate this index retrospectively in a larger and independent HCC cohort of 2706 Italian HCC patients, and to evaluate a possible relationship between the index and liver function parameters. The scores in the HCC Aggressiveness Index were again found to significantly relate to patient survival. Furthermore, in a multiple logistic regression model of the Aggressiveness Index score categories, there were significant differences in several liver parameter terciles amongst the score categories, suggesting a relationship of liver function to tumor aggressiveness. It was concluded that a prognostically significant Tumor Aggressiveness Index was validated and was found to be related to levels of some common liver function parameters.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels

Carr¹,

Guerra²

2016

J Integr Oncol

View full text Add to dashboard Cite

show abstract

“…Tumor vessel density, which represents angiogenesis, has prognostic value in various malignant tumors, including glioma (20). Angiogenesis is controlled by the interplay between numerous positive and negative factors (21).…”

Section: Discussionmentioning

confidence: 99%

The correlation of microRNA-181a and target genes with poor prognosis of glioblastoma patients

Huang¹,

Zhao²,

Weng³

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. To investigate the expression and clinical significance of miR-181a and its target genes in glioblastoma multiforme (GBM), the expression levels of miR-181a and three target genes in human normal brain tissues and GBM were analyzed in silico using gene microarray, Gene Ontology, KEGG pathway and hierarchical clustering analysis followed by validation with quantitative RT-PCR. Our results show that miR-181a is down-regulated in GBM patients. The three target genes, ANGPT2, ARHGAP18 and LAMC1, are negatively correlated with the expression of miR-181a. Moreover, high expression of ANGPT2 or LAMC1 together with large size of GBM is correlated with a shorter median overall survival. In conclusion, our results showed that miR-181a and it targets ANGPT2 and LAMC1 might be predictors of prognosis in GBM patients.

show abstract

“…Although hematopoietic stem cell transplantation can help acute myeloid leukemia patients achieve long-term disease-free survival or even a cure, it is an expensive treatment, and hence, is not desired by all patients. Chemotherapy is still the main treatment for acute myeloid leukemia (Wu et al, 2012;Champlin, 2013;Martner et al, 2013). There is continuous in-depth research into the cytogenetics of this disease, its mechanism of occurrence and development, and the effectiveness of chemotherapeutic drugs.…”

Section: Discussionmentioning

confidence: 99%

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Su¹,

Wang²,

Zhou³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The present study aimed to explore the changes in serum endostatin and fibroblast growth factor 19 (FGF-19) in acute myeloid leukemia patients, and to determine their effects on chemotherapeutic sensitivity. Sixty acute myeloid leukemia patients and 30 healthy controls were included in the study. Patient serum endostatin and FGF-19 levels were measured on admission, and then, standard chemotherapy was administered. The patients were divided into 2 groups according to chemotherapeutic effects: 21 patients in the chemotherapeutic sensitivity group (complete remission + partial remission) and 39 in the chemotherapeutic resistance group (no remission + degradation). A receiver operating characteristic (ROC) curve was used to analyze the relationship of serum endostatin and FGF-19 levels with chemotherapeutic sensitivity in acute myeloid leukemia patients. The levels of serum endostatin and FGF-19 in acute myeloid leukemia patients before chemotherapy were significantly higher than those in the control group. Moreover, these levels significantly decreased after chemotherapy (P < 0.01). The levels of serum endostatin and FGF-19 in the chemotherapeutic sensitivity group were lower than those in the chemotherapeutic resistance group, both before and after chemotherapy (P < 0.05 and P < 0.01, respectively). ROC curve analysis showed that the predictive values of endostatin and FGF-19 were good, and there was no significant difference between these results. In conclusion, serum endostatin and FGF-19 can be used as predictors of chemotherapeutic sensitivity for acute myeloid leukemia patients, and may be important for determining prognosis.

show abstract

Role of the microenvironment in hepatocellular carcinoma development and progression

Cited by 112 publications

References 111 publications

An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels

An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels

The correlation of microRNA-181a and target genes with poor prognosis of glioblastoma patients

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Contact Info

Product

Resources

About